{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:00:26Z","timestamp":1787259626721,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) affects 6\u201310% of adults and often remains undiagnosed until advanced stages, leading to inadequate management. This study compared diagnosed, proxy-diagnosed, and undiagnosed CKD patients regarding prevalence, clinical assessment, nephroprotective treatment, healthcare utilization, and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study analyzed Region Halland's healthcare data for adults meeting KDIGO CKD-confirmed criteria for the year 2019. Patients were categorized as diagnosed CKD (ICD-coded), proxy-diagnosed CKD (CKD-related diagnoses), or undiagnosed CKD (meeting CKD criteria without an ICD CKD diagnosis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 20,488 CKD patients, 21% had diagnosed CKD, 18% proxy-diagnosed CKD, and 61% undiagnosed CKD. Mean ages were 76.4, 62.4, and 81.8 years, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Blood pressure follow-up was carried out in diagnosed CKD (88%) versus 67% and 80% in the proxy-diagnosed and undiagnosed groups. eGFR was tested in 66% overall (73% diagnosed, 53% proxy-diagnosed, 66% undiagnosed), while urine albumin-to-creatinine ratio (UACR) testing was performed in 27% overall (50%, 20%, and 21%, respectively). Renin-angiotensin system inhibitors were prescribed to 45% overall (51%, 28%, and 47%, respectively). The adjusted hospitalization risk was 2.71 (CI: 2.59\u20132.84) in diagnosed CKD and 1.38 (CI: 1.31\u20131.46) in proxy-diagnosed CKD. Adjusted all-cause mortality hazard ratios were 2.22 (CI: 1.95\u20132.52) and 1.31 (CI: 1.08\u20131.60), respectively. Stratified sensitivity analyses by CKD stage confirmed these associations, though the strength varied.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with complex comorbidities, more advanced CKD, and frequent hospitalizations are more likely to be diagnosed with CKD\u00a0and receive better follow-up care. Proxy-diagnosed CKD was common and associated with suboptimal management. These findings emphasize the need for consistent and accurate CKD identification to improve outcomes and optimize care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-025-02414-2","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T18:23:07Z","timestamp":1758910987000},"page":"2809-2820","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Differences in chronic kidney disease management based on identification and diagnosis in a population-based observational study"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7256-8323","authenticated-orcid":false,"given":"Michael","family":"Olszewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0832-025X","authenticated-orcid":false,"given":"Karl","family":"Bjurstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4068-0341","authenticated-orcid":false,"given":"Markus","family":"Lingman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-1153","authenticated-orcid":false,"given":"Dan","family":"Henrohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1861-1851","authenticated-orcid":false,"given":"Poyan","family":"Shojaiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2850-2221","authenticated-orcid":false,"given":"Magnus","family":"Garell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3956-6103","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Agvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"2414_CR1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12325-020-01568-8","volume":"38","author":"M Murton","year":"2021","unstructured":"Murton M, Goff-Leggett D, Bobrowska A et al (2021) Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review. Adv Ther 38:180\u2013200","journal-title":"Adv Ther"},{"key":"2414_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"B Bikbov","year":"2020","unstructured":"Bikbov B, Purcell CA, Levey AS et al (2020) Global. regional. and national burden of chronic kidney disease. 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395:709\u201333","journal-title":"Lancet"},{"key":"2414_CR3","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/ndt\/gfw354","volume":"31","author":"A Gasparini","year":"2016","unstructured":"Gasparini A, Evans M, Coresh J et al (2016) Prevalence and recognition of chronic kidney disease in Stockholm healthcare. Nephrol Dial Transplant 31:2086\u201394","journal-title":"Nephrol Dial Transplant"},{"key":"2414_CR4","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Chronic Kidney Disease (2017) Chronic kidney disease. Lancet 389:1238\u201352","journal-title":"Lancet"},{"key":"2414_CR5","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/ki.2011.368","volume":"80","author":"WG Couser","year":"2011","unstructured":"Couser WG, Remuzzi G, Mendis S et al (2011) The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 80:1258\u201370","journal-title":"Kidney Int"},{"key":"2414_CR6","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A et al (2018) Forecasting life expectancy years of life lost. and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories. Lancet 392:2052\u201390","journal-title":"Lancet"},{"key":"2414_CR7","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, DAPA-CKD Trial Committees and Investigators et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u201346","journal-title":"N Engl J Med"},{"key":"2414_CR8","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","volume":"139","author":"D Fitchett","year":"2019","unstructured":"Fitchett D, Inzucchi SE, Cannon CP et al (2019) Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation 139:1384\u201395","journal-title":"Circulation"},{"key":"2414_CR9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.2337\/dc21-1944","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing P, Burgess E, Agarwal R, FIDELIO-DKD Investigators et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD study. Diabetes Care. 45:888\u201397","journal-title":"Diabetes Care."},{"key":"2414_CR10","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ki.2014.31","volume":"85","author":"C Wanner","year":"2014","unstructured":"Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members (2014) Kdigo clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85:1303\u20139","journal-title":"Kidney Int"},{"key":"2414_CR11","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117\u2013S314","journal-title":"Kidney Int"},{"issue":"1","key":"2414_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-01792-y","volume":"21","author":"GA Nichols","year":"2020","unstructured":"Nichols GA, D\u00e9ruaz-Luyet A, Brodovicz KG et al (2020) Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes. BMC Nephrol 21(1):167","journal-title":"BMC Nephrol"},{"key":"2414_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN et al (2022) Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int 102:990\u20139","journal-title":"Kidney Int"},{"key":"2414_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069313","volume":"13","author":"B Agvall","year":"2023","unstructured":"Agvall B, Ashfaq A, Bjurstr\u00f6m K et al (2023) Characteristics, management and outcomes in patients with CKD in a healthcare region in Sweden: a population-based, observational study. BMJ Open. 13:e069313","journal-title":"BMJ Open."},{"key":"2414_CR15","volume":"20","author":"J Sundstr\u00f6m","year":"2022","unstructured":"Sundstr\u00f6m J, Bodegard J, Bollmann A, CaReMe CKD Investigators et al (2022) Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2\u00b74 million patients from 11 countries: the careme CKD study. Lancet Reg Health 20:100438","journal-title":"Lancet Reg Health"},{"key":"2414_CR16","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1007\/s12325-023-02482-5","volume":"40","author":"N Tangri","year":"2023","unstructured":"Tangri N, Peach EJ, Franz\u00e9n S et al (2023) Patient management and clinical outcomes associated with a recorded diagnosis of stage 3 chronic kidney disease: the REVEAL-CKD study. Adv Ther 40:2869\u201385","journal-title":"Adv Ther"},{"key":"2414_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14282","volume":"18","author":"N Tangri","year":"2024","unstructured":"Tangri N, Alvarez CS, Arnold M et al (2024) Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real-world settings: Insights from REVEAL-CKD. Eur J Clin Invest. 18:e14282","journal-title":"Eur J Clin Invest."},{"key":"2414_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.xkme.2021.03.014","volume":"3","author":"CD Chu","year":"2021","unstructured":"Chu CD, Chen MH, McCulloch CE et al (2021) Patient awareness of CKD: a systematic review and meta-analysis of patient-oriented questions and study setting. Kidney Med. 3:576-585.e1","journal-title":"Kidney Med."},{"key":"2414_CR19","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/ije\/dyz262","volume":"49","author":"A Ashfaq","year":"2020","unstructured":"Ashfaq A, L\u00f6nn S, Nilsson H et al (2020) Data resource profile: regional healthcare information platform in Halland. Sweden. Int J Epidemiol 49:738\u20139f","journal-title":"Int J Epidemiol"},{"issue":"3","key":"2414_CR20","first-page":"1","volume":"2013","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO (2012) clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013(3):1\u2013150","journal-title":"Kidney Int Suppl"},{"key":"2414_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1515\/cclm-2013-0741","volume":"52","author":"U Nyman","year":"2014","unstructured":"Nyman U, Grubb A, Larsson A et al (2014) The revised Lund-Malm\u00f6 GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population. Clin Chem Lab Med 52:815\u201324","journal-title":"Clin Chem Lab Med"},{"key":"2414_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","volume":"99","author":"MG Shlipak","year":"2021","unstructured":"Shlipak MG, Tummalapalli SL, Boulware LE, Conference Participants et al (2021) The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int 99:34\u201347","journal-title":"Kidney Int"},{"key":"2414_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067386","volume":"13","author":"N Tangri","year":"2023","unstructured":"Tangri N, Moriyama T, Schneider MP et al (2023) Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan, and the USA: results from the multinational observational REVEAL-CKD study. BMJ Open. 13:e067386","journal-title":"BMJ Open."},{"key":"2414_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12875-015-0235-8","volume":"16","author":"SD Fraser","year":"2015","unstructured":"Fraser SD, Parkes J, Culliford D et al (2015) Timeliness in chronic kidney disease and albuminuria identification: a retrospective cohort study. BMC Fam Pract 16:18","journal-title":"BMC Fam Pract"},{"key":"2414_CR25","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.2337\/dc20-2715","volume":"44","author":"N Stempniewicz","year":"2021","unstructured":"Stempniewicz N, Vassalotti JA, Cuddeback JK et al (2021) Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations. Diabetes Care 44:2000\u20139","journal-title":"Diabetes Care"},{"key":"2414_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18169","volume":"2","author":"KR Tuttle","year":"2019","unstructured":"Tuttle KR, Alicic RZ, Duru OK et al (2019) Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open 2:e1918169","journal-title":"JAMA Netw Open"},{"key":"2414_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V et al (2016) Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67:728\u201341","journal-title":"Am J Kidney Dis"},{"key":"2414_CR28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","volume":"4","author":"WG Herrington","year":"2016","unstructured":"Herrington WG, Emberson J, Mihaylova B, Cholesterol Treatment Trialists\u2019 (CTT) Collaboration et al (2016) Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 4:829\u201339","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2414_CR29","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2012.16817","volume":"308","author":"SI Hallan","year":"2012","unstructured":"Hallan SI, Matsushita K, Sang Y, Chronic Kidney Disease Prognosis Consortium et al (2012) Age and association of kidney measures with mortality and end-stage renal disease. JAMA 308:2349\u201360","journal-title":"JAMA"},{"key":"2414_CR30","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1093\/ndt\/gfad033","volume":"38","author":"AJ Jonsson","year":"2023","unstructured":"Jonsson AJ, Lund SH, Eriksen BO et al (2023) Association of eGFR and mortality with use of a joint model: results of a nationwide study in Iceland. Nephrol Dial Transplant 38:2201\u201312","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02414-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02414-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02414-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:59:49Z","timestamp":1777564789000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/9\/2809\/8462690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2414"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02414-2","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Poyan Shojaiyan (PS) and Dan Henrohn (DH) are employed by AstraZeneca (AZ). The remaining authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Swedish Ethical Review Board at the Ume\u00e5 Department of Medicine. with registration number 2021-04609. Granted approval for this study. Informed consent was waived. and this study procedure was authorized by the Swedish Ethical Review Board. Ume\u00e5 Department of Medicine. All methodologies employed in this research adhered strictly to the applicable guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}}]}}